Orphazyme AS (OZYMF)

[Traderprofessional1]

$ORPH WILL HIT $100.00 BY TODAY An FDA ruling for the product is expected today and according to ORPH, “Orphazyme's applications for arimoclomol (to be branded MIPLYFFATM) for Niemann-Pick disease type C (NPC) are under priority review with the U.S. Food and Drug Administration, with an expected PDUFA action date of June 17 2021.”